Back to News
Market Impact: 0.2
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
Source: businesswire.com
Healthcare & BiotechCompany Fundamentals
Verastem Oncology announced new molecular profiling and external control-arm analyses from the RAMP 201 study supporting clinical outcomes for avutometinib plus defactinib in recurrent low-grade serous ovarian cancer (LGSOC). The headline provides no efficacy figures, regulatory updates, or financial details, limiting the immediate valuation impact despite the positive clinical-data framing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
VSTM0.72
More News
- Anthropic warns government attitudes may hurt customer ties, IPO prospectus shows: Reuters
- Your health insurance premiums may take a big jump in 2027 — here's why
- Paramount and Warner Bros. Discovery to Merge Into Skydance (SKYD). Will Skydance Achieve David Ellison’s "Quality Storytelling" Vision?
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Tesla reports 486,532 vehicle deliveries for third quarter, topping expectation